+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Drug Eluting Stents (DES) - Medical Devices Pipeline Assessment, 2020

  • ID: 5180229
  • Report
  • October 2020
  • Region: Global
  • 162 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Abbott Vascular Inc
  • Biotronik AG
  • Columbia University
  • Elixir Medical Corp
  • Kaneka Corp
  • MicroPort Scientific Corp
  • MORE
Summary

The publisher's Medical Devices sector report, “Drug Eluting Stents (DES)-Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Drug Eluting Stents (DES) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

DES release drugs locally and can be coated with a polymeric material. The stent releases an antiproliferative or immunosuppressive drug over time, leaving behind the metallic stent in the artery.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
  • Extensive coverage of the Drug Eluting Stents (DES) under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Drug Eluting Stents (DES) and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment/industry
Reasons to Buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Drug Eluting Stents (DES) under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Abbott Vascular Inc
  • Biotronik AG
  • Columbia University
  • Elixir Medical Corp
  • Kaneka Corp
  • MicroPort Scientific Corp
  • MORE
1 Table of Contents

2 Introduction
2.1 Drug Eluting Stents (DES) Overview

3 Products under Development
3.1 Drug Eluting Stents (DES)-Pipeline Products by Stage of Development
3.2 Drug Eluting Stents (DES)-Pipeline Products by Territory
3.3 Drug Eluting Stents (DES)-Pipeline Products by Regulatory Path
3.4 Drug Eluting Stents (DES)-Pipeline Products by Estimated Approval Date
3.5 Drug Eluting Stents (DES)-Ongoing Clinical Trials

4 Drug Eluting Stents (DES)-Pipeline Products under Development by Companies
4.1 Drug Eluting Stents (DES) Companies-Pipeline Products by Stage of Development
4.2 Drug Eluting Stents (DES)-Pipeline Products by Stage of Development

5 Drug Eluting Stents (DES) Companies and Product Overview

6 Drug Eluting Stents (DES)-Recent Developments

7 Appendix

List of Tables
Table 1: Drug Eluting Stents (DES)-Pipeline Products by Stage of Development
Table 2: Drug Eluting Stents (DES)-Pipeline Products by Territory
Table 3: Drug Eluting Stents (DES)-Pipeline Products by Regulatory Path
Table 4: Drug Eluting Stents (DES)-Pipeline Products by Estimated Approval Date
Table 5: Drug Eluting Stents (DES)-Ongoing Clinical Trials
Table 6: Drug Eluting Stents (DES) Companies-Pipeline Products by Stage of Development
Table 7: Drug Eluting Stents (DES)-Pipeline Products by Stage of Development
Table 8: Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 9: Xience SBA Everolimus Eluting Coronary Stent System-Product Status
Table 10: Xience SBA Everolimus Eluting Coronary Stent System-Product Description
Table 11: XIENCE Thin man DES-Product Status
Table 12: XIENCE Thin man DES-Product Description
Table 13: ZoMaxx Drug Eluting Coronary Stent System-Product Status
Table 14: ZoMaxx Drug Eluting Coronary Stent System-Product Description
Table 15: Abbott Vascular Inc-Ongoing Clinical Trials Overview
Table 16: Xience SBA Everolimus Eluting Coronary Stent System-A Multi-center, Randomized, Controlled Trial to Demonstrate the Safety and Effectiveness of the MiStent II for the Revascularization of Coronary Arteries: CRYSTAL Study
Table 17: Xience SBA Everolimus Eluting Coronary Stent System-A Prospective Global Randomized Trial Assessing the Safety and Efficacy of the BuMA Supreme Biodegradable Drug Coated Coronary Stent System for Coronary Revascularization in Patients with Stable Coronary Artery Disease or Non-ST Segment Elevation Acute Coronary Syndromes
Table 18: Xience SBA Everolimus Eluting Coronary Stent System-A Prospective Multicenter Randomized Post Market All-comer Trial to Assess the Safety and Effectiveness of the Supraflex Sirolimus-eluting Coronary Stent System for the Treatment of Atherosclerotic Lesion(s)
Table 19: Xience SBA Everolimus Eluting Coronary Stent System-Polish Bifurcation Optimal Treatment Strategy Study for Left Main Bifurcation Percutaneous Coronary Intervention (PCI)
Table 20: Adcomp Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 21: Dual Drug Eluting Stent-Product Status
Table 22: Dual Drug Eluting Stent-Product Description
Table 23: Advanced Bifurcation Systems Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 24: Stenting System-Drug Eluting Stent-Product Status
Table 25: Stenting System-Drug Eluting Stent-Product Description
Table 26: Aeon Bioscience Pipeline Products & Ongoing Clinical Trials Overview
Table 27: Drug Eluting Stent-Product Status
Table 28: Drug Eluting Stent-Product Description
Table 29: AlviMedica Medical Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 30: Cre8 DES-Product Status
Table 31: Cre8 DES-Product Description
Table 32: Cre8 EVO DES-Product Status
Table 33: Cre8 EVO DES-Product Description
Table 34: DES-Coracto-Product Status
Table 35: DES-Coracto-Product Description
Table 36: AlviMedica Medical Technologies Inc-Ongoing Clinical Trials Overview
Table 37: Cre8 DES-A Prospective, Multi-center, Open Label, Randomized Controlled, Two Arm Study Evaluating Safety and Efficacy of the Permanent Polymer Zotarolimus Eluting Stent Resolute Integrity Compared to the Polymer Free Amphilimus Eluting Stent Cre8
Table 38: Cre8 DES-A Prospective, Multi-center, Randomized Controlled Trial Evaluating the Safety and Efficacy of the CRE8 Sirolimus-Eluting Stent Versus the RESOLUTE Zotarolimus-eluting Stent in the Treatment of Patients with De Novo Coronary Artery Lesions
Table 39: Cre8 DES-A Prospective, Multi-center, Single-arm Observational Registry Trial Evaluating the Safety and Efficacy of CRE8 Sirolimus-Eluting Stent in the Treatment of Patients With De Novo Coronary Artery Lesions
Table 40: Cre8 DES-Prove ART (Abluminal Reservoir Technology) Clinical Benefit in Alla Comers Patients

List of Figures
Figure 1: Drug Eluting Stents (DES)-Pipeline Products by Stage of Development
Figure 2: Drug Eluting Stents (DES)-Pipeline Products by Territory
Figure 3: Drug Eluting Stents (DES)-Pipeline Products by Regulatory Path
Figure 4: Drug Eluting Stents (DES)-Pipeline Products by Estimated Approval Date
Figure 5: Drug Eluting Stents (DES)-Ongoing Clinical Trials
Note: Product cover images may vary from those shown
3 of 3
  • Abbott Vascular Inc
  • Adcomp Technologies Inc.
  • Advanced Bifurcation Systems Inc
  • Aeon Bioscience
  • AlviMedica Medical Technologies Inc
  • B. Braun Melsungen AG
  • Biosensors International Group Ltd
  • Biotronik AG
  • Biotronik SE & Co KG
  • Boston Scientific Corp
  • Cardionovum GmbH
  • Columbia University
  • Concept Medical Inc
  • Cordis Corp
  • DISA Vascular (Pty) Ltd
  • Elixir Medical Corp
  • Envision Scientific Pvt Ltd
  • I.B.S. S.p.A.
  • InspireMD Inc
  • JW Medical Systems Ltd
  • Kaneka Corp
  • Liaoning Biomedical Materials R&D Center Co Ltd
  • MangoGen Pharma Inc
  • Medinol Ltd
  • Medtronic Plc
  • MicroPort Scientific Corp
  • MIV Therapeutics Inc
  • NuVascular Technologies Inc
  • Relisys Medical Devices Ltd
  • REVA Medical Inc
  • Shanghai Bio-heart Biological Technology Co Ltd
  • Sino Medical Sciences Technology Inc
  • Stentys SA
  • Svelte Medical Systems Inc
  • Terumo Corp
  • TissueGen Inc
  • University of Strathclyde
  • VasoTech Inc.
Note: Product cover images may vary from those shown
Adroll
adroll